Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Billionaire Carl Icahn Trims Stake in Hologic Inc. (HOLX) but Still Likes the Company

 

Hologic has undergone a massive overhaul since Carl Icahn acquired an activist stake in the company back in November 2013. The company had been performing extremely poorly when Carl Icahn initiated his position in Hologic. The healthcare-focused company had experienced two years of accounting losses, failed to generate any significant gains for shareholders and involved in weak and destructive acquisitions. For instance, Hologic acquired the molecular diagnostics company Gen-Probe in 2012 for $3.7 billion, which resulted in a $1.1 billion write-down within a year. In 2014, Carl Icahn managed to appoint two members on the Board of the company and also pushed out most of the company’s management, with several key management positions at the company being replaced last year. Eventually, the management overhauls were very effective, as the company managed to deliver a positive net income for only the second time since 2007. It seems that the management overhauls at Hologic are completed and the company continues to deliver strong financial performance. 

 

Just a few days ago, Hologic has announced the financial results for the third quarter of the fiscal year 2015 that ended June 27, which have not disappointed the investors. The company posted revenue of $693.9 million, up by 9.7% year-over-year on a reported basis. By the same token, the company’s GAAP earnings per share (EPS) advanced by an annual 150% to $0.10. Indeed, the third quarter financial results of Hologic reflect the positive changes that have taken place at the company over the last years. Steve MacMillan, the Chairman, President and Chief Executive Officer at Hologic, suggested that these financial results demonstrate the significant progress achieved by Hologic in building a company that can grow on both the top and bottom lines. Another hedge fund that has been bullish on Hologic Inc. (NASDAQ:HOLX) since 2013 is Raplh V. Whitworth’s Relational Investors, holding an ownership stake of 12.97 million shares.

Disclosure: None

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading...